The DOJ is probing Andreessen Horowitz over competing board seats

The US Justice Department is investigating Andreessen Horowitz over whether its partners improperly sit on the boards of competing artificial intelligence companies.

Bloomberg reported the probe on Monday. The two companies at the center are Databricks and Fivetran, both backed by the firm, according to Fortune. People describing the matter said the review is roughly a year old and that no final decision has been made, so it could still end with no action.

The legal theory is a board interlock. Section 8 of the Clayton Act bars the same person from sitting on the boards of two competing companies. The live question, as Implicator lays out, is whether separate a16z partners function as the firm's agents on rival boards.

Reporting points to Ben Horowitz's seat at Databricks and Martin Casado's seat at Fivetran. If prosecutors treat the firm, rather than the individual director, as the interlocking party, that stretches a decades-old rule onto the way modern venture funds spread partners across a portfolio.

The politics made the story travel. Co-founder Marc Andreessen has become a prominent Trump backer and adviser, which is part of why Forbes and The Next Web framed the review as notable beyond the antitrust mechanics. Monday's account is the first public confirmation of a probe that has apparently been quiet for months.

A Section 8 conclusion would not carry the drama of a merger challenge, but it has teeth. It can force a director off a board, or push a firm to give up the appointment rights it negotiated when it wrote the check.

Databricks and Fivetran both sit in the data-infrastructure layer that feeds today's agentic AI systems. For a sector where the biggest venture firms hold seats across dozens of overlapping AI and data startups, any precedent here would ripple across the cap tables of the whole stack.

Nothing has been decided. A year-long review that surfaces with no charges is a common outcome. How a marquee VC parks its partners on competing boards is now an antitrust question, not just a governance footnote.